Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults

• Published in: Scientific reports 2019-08, Vol.9 (1), p.12210-9, Article 12210
• Main Authors: Madempudi, Ratna Sudha, Ahire, Jayesh J., Neelamraju, Jayanthi, Tripathi, Anirudh, Nanal, Satyavrat
• Format: Article
• Language: English
• Subjects: 692/4020/1503/1581/2071; 692/4020/2741/2135; Adult; Bacillus coagulans; Clinical trials; Cytokines - metabolism; Female; Humanities and Social Sciences; Humans; Inflammation; Interleukin 10; Interleukin 12; Interleukin 6; Intestine; Irritable bowel syndrome; Irritable Bowel Syndrome - metabolism; Irritable Bowel Syndrome - pathology; Irritable Bowel Syndrome - therapy; Male; Management; Middle Aged; multidisciplinary; Pain; Patients; Probiotics; Probiotics - administration & dosage; Science; Science (multidisciplinary); Tumor necrosis factor-α
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-019-48554-x

The therapeutic effects of B . coagulans Unique IS2 have been well established in children with irritable bowel syndrome (IBS), but its efficacy in adults remain under reported. Thus, in this study the efficacy of B . coagulans Unique IS2 in the management of IBS symptoms in adults was investigated. Patients ( n  = 153) fulfilling Rome III criteria were provided placebo capsules for a 2 weeks run-in period. Only patients satisfying compliance criteria ( n  =  136 ) were randomized (double blind) to receive either B . coagulans Unique IS2 (2 billion CFU) or placebo capsules daily for 8 weeks. Reduction of abdominal discomfort/pain intensity and increase in complete spontaneous bowel movements were analyzed as primary end points. Other clinical symptoms of IBS and serum cytokines were also evaluated. B . coagulans Unique IS2 showed significant improvement in primary and secondary endpoints, as compared to placebo. Haematology of both the arms remained normal. No significant changes in pro- (IL-6, IL-12, TNF-α, INF- γ) and anti-inflammatory cytokine (IL-10) levels were detected at the end of B . coagulans treatment (8 weeks) as compared to placebo. B . coagulans was well tolerated with no severe adverse events to report. Overall, the results demonstrate that B . coagulans Unique IS2 is efficacious in the management of IBS symptoms in adults (18–60 years).